Chief Executive Officer, Arcus
Terry Rosen has been leading R&D organizations in the biotechnology and pharmaceutical industries for over 35 years. In 2015, he co-founded Arcus Biosciences, a drug discovery company focused on the treatment of cancer. Previously, he was co-founder and CEO of Flexus Biosciences, a company created to develop drugs to reverse tumor-induced immunosuppression. Flexus was acquired by Bristol-Myers Squibb in early 2015 for $1.25B. Prior to Flexus, Dr. Rosen served as Vice President, Therapeutic Discovery at Amgen, joining Amgen in 2004 with the acquisition of Tularik. Dr. Rosen held executive positions at Tularik, including Executive Vice President of Operations, and held scientific and management positions at Pfizer and Abbott Laboratories. Dr. Rosen serves on the Board of Trustees of The Salk Institute and the UC Berkeley Foundation and on the Scientific Advisory Board of the University of Michigan Life Sciences Institute and the Caltech Biology & Bioengineering Chair’s Council.